CEPI
@cepi.net
Coalition for Epidemic Preparedness Innovations (CEPI). Working to end epidemics & pandemics by developing new vaccines for a safer world. #100DaysMission
What if it took 100 days to make a safe and effective vaccine against any virus?
We could stay one step ahead of infectious diseases and outbreaks could be stopped before they ever spiralled into pandemics #100DaysMission
https://cepi.net/cepi-20-and-100-days-mission
We could stay one step ahead of infectious diseases and outbreaks could be stopped before they ever spiralled into pandemics #100DaysMission
https://cepi.net/cepi-20-and-100-days-mission
CEPI 2.0 and the 100 Days Mission
CEPI’s 2022-2026 strategy, known as CEPI 2.0, is helping to Prepare, Transform, and Connect the world so that it can respond to the next Disease X threat with a new vaccine in just three months.
cepi.net
December 23, 2025 at 10:32 AM
What if it took 100 days to make a safe and effective vaccine against any virus?
We could stay one step ahead of infectious diseases and outbreaks could be stopped before they ever spiralled into pandemics #100DaysMission
https://cepi.net/cepi-20-and-100-days-mission
We could stay one step ahead of infectious diseases and outbreaks could be stopped before they ever spiralled into pandemics #100DaysMission
https://cepi.net/cepi-20-and-100-days-mission
The Biospecimen Sourcing Initiative is a new global resource that aims to facilitate the timely, coordinated and ethical sourcing of biospecimens in an outbreak.
Specimens provide scientists with insights into the virus and how the body fends off an infection ⤵️ @path.org
cepi.net/disease-outb...
Specimens provide scientists with insights into the virus and how the body fends off an infection ⤵️ @path.org
cepi.net/disease-outb...
Disease outbreak survivors are key to future preparedness
A new global biospecimen access network aims to collect and share biological samples consistently and equitably.
cepi.net
December 20, 2025 at 1:49 PM
The Biospecimen Sourcing Initiative is a new global resource that aims to facilitate the timely, coordinated and ethical sourcing of biospecimens in an outbreak.
Specimens provide scientists with insights into the virus and how the body fends off an infection ⤵️ @path.org
cepi.net/disease-outb...
Specimens provide scientists with insights into the virus and how the body fends off an infection ⤵️ @path.org
cepi.net/disease-outb...
Reposted by CEPI
🚨 Exciting news for global health security: CEPI is supporting a pivotal Phase 3 trial to advance Moderna’s mRNA H5 pandemic influenza vaccine candidate (mRNA-1018) towards licensure and enable rapid, equitable access in the event of a flu pandemic.
CEPI to Fund Pivotal Phase 3 Trial for Moderna’s mRNA Pandemic Influenza Candidate
Partnership strengthens global preparedness against a significant pandemic threat
cepi.net
December 18, 2025 at 1:44 PM
🚨 Exciting news for global health security: CEPI is supporting a pivotal Phase 3 trial to advance Moderna’s mRNA H5 pandemic influenza vaccine candidate (mRNA-1018) towards licensure and enable rapid, equitable access in the event of a flu pandemic.
🚨 Exciting news for global health security: CEPI is supporting a pivotal Phase 3 trial to advance Moderna’s mRNA H5 pandemic influenza vaccine candidate (mRNA-1018) towards licensure and enable rapid, equitable access in the event of a flu pandemic.
CEPI to Fund Pivotal Phase 3 Trial for Moderna’s mRNA Pandemic Influenza Candidate
Partnership strengthens global preparedness against a significant pandemic threat
cepi.net
December 18, 2025 at 1:44 PM
🚨 Exciting news for global health security: CEPI is supporting a pivotal Phase 3 trial to advance Moderna’s mRNA H5 pandemic influenza vaccine candidate (mRNA-1018) towards licensure and enable rapid, equitable access in the event of a flu pandemic.
In our Innovation for Impact story, we spoke with icddr,b’s Dr K Zaman and CEPI’s Nipah programme lead, Rick Jarman, to explore the impact of CEPI's $150 million Nipah R&D portfolio and how it's helping the world prepare to confront one of the most lethal viral threats.
Closing in on protection against deadly Nipah virus
Discover how CEPI and partners are preparing the world to face down a future Nipah virus outbreak.
cepi.net
December 17, 2025 at 12:46 PM
In our Innovation for Impact story, we spoke with icddr,b’s Dr K Zaman and CEPI’s Nipah programme lead, Rick Jarman, to explore the impact of CEPI's $150 million Nipah R&D portfolio and how it's helping the world prepare to confront one of the most lethal viral threats.
CEPI is backing a second $198,000 project with GENSPEED Biotech to speed up vaccine quality testing. The rapid, automated assay can detect residual proteins in ~20 minutes—far faster than today’s 3-hour methods.
December 12, 2025 at 10:53 AM
CEPI is backing a second $198,000 project with GENSPEED Biotech to speed up vaccine quality testing. The rapid, automated assay can detect residual proteins in ~20 minutes—far faster than today’s 3-hour methods.
Reposted by CEPI
📢 A world first: CEPI-funded Nipah virus vaccine candidate enters Phase II clinical trials.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
University of Oxford launches world’s first Phase II Nipah virus vaccine trial
CEPI-funded Phase II trial launches in Bangladesh
cepi.net
December 9, 2025 at 10:16 AM
📢 A world first: CEPI-funded Nipah virus vaccine candidate enters Phase II clinical trials.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
Reposted by CEPI
During a disease outbreak, #VaccineDevelopment efforts rely on biological samples from survivors. With @cepi.net, we conducted a simulation exercise to test the design and development of a new network that aims to collect and share these samples consistently and equitably: https://bit.ly/440DQ7O
December 8, 2025 at 4:19 PM
During a disease outbreak, #VaccineDevelopment efforts rely on biological samples from survivors. With @cepi.net, we conducted a simulation exercise to test the design and development of a new network that aims to collect and share these samples consistently and equitably: https://bit.ly/440DQ7O
Reposted by CEPI
The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus.
Find out more ⬇️ @ovg.ox.ac.uk | @cepi.net
Find out more ⬇️ @ovg.ox.ac.uk | @cepi.net
First volunteer receives Lassa Fever vaccine in cutting-edge Oxford
The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus.
www.ox.ac.uk
December 9, 2025 at 2:24 PM
The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus.
Find out more ⬇️ @ovg.ox.ac.uk | @cepi.net
Find out more ⬇️ @ovg.ox.ac.uk | @cepi.net
📢 A world first: CEPI-funded Nipah virus vaccine candidate enters Phase II clinical trials.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
University of Oxford launches world’s first Phase II Nipah virus vaccine trial
CEPI-funded Phase II trial launches in Bangladesh
cepi.net
December 9, 2025 at 10:16 AM
📢 A world first: CEPI-funded Nipah virus vaccine candidate enters Phase II clinical trials.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
📣 The Republic of Korea's Ministry of Foreign Affairs has announced new $18.9 million support to CEPI to bolster efforts to protect against the next deadly pandemic and boost international health security 🇰🇷
cepi.net/korea-steps-...
cepi.net/korea-steps-...
Korea steps up pandemic response with $18.9m investment in CEPI
The new financial contribution agreement was signed today at a meeting with Ambassador Minjeong Seo, Ambassador of the Republic of Korea to Norway and CEPI CEO Dr Richard Hatchett.
cepi.net
December 5, 2025 at 3:08 PM
📣 The Republic of Korea's Ministry of Foreign Affairs has announced new $18.9 million support to CEPI to bolster efforts to protect against the next deadly pandemic and boost international health security 🇰🇷
cepi.net/korea-steps-...
cepi.net/korea-steps-...
📣The first volunteer has received a dose of @ox.ac.uk's Lassa fever vaccine candidate in a Phase I trial funded by CEPI.
The deadly haemmorhagic fever causes annual outbreaks across West Africa, however no vaccine is currently available for use (1/2).
The deadly haemmorhagic fever causes annual outbreaks across West Africa, however no vaccine is currently available for use (1/2).
First volunteer receives Lassa fever vaccine in cutting-edge Oxford trial
The CEPI-funded research study will assess the safety and immune response of Oxford's ChAdOx1 Lassa vaccine.
cepi.net
December 4, 2025 at 12:23 PM
📣The first volunteer has received a dose of @ox.ac.uk's Lassa fever vaccine candidate in a Phase I trial funded by CEPI.
The deadly haemmorhagic fever causes annual outbreaks across West Africa, however no vaccine is currently available for use (1/2).
The deadly haemmorhagic fever causes annual outbreaks across West Africa, however no vaccine is currently available for use (1/2).
Last month, CEPI had the pleasure of welcoming Marjolijn Sonnema, Vice Minister of Health of the Netherlands, to The
Aurum Institute in Johannesburg.
Aurum Institute in Johannesburg.
December 1, 2025 at 3:02 PM
Last month, CEPI had the pleasure of welcoming Marjolijn Sonnema, Vice Minister of Health of the Netherlands, to The
Aurum Institute in Johannesburg.
Aurum Institute in Johannesburg.
CEPI’s November newsletter is out! 🗞️
This edition spotlights recent regulatory “pressure test” simulations in Brasilia and Mombasa, early clinical progress on a Lassa fever vaccine, new partnerships to speed up vaccine manufacturing and release, and lots more.
www.linkedin.com/pulse/pressu...
This edition spotlights recent regulatory “pressure test” simulations in Brasilia and Mombasa, early clinical progress on a Lassa fever vaccine, new partnerships to speed up vaccine manufacturing and release, and lots more.
www.linkedin.com/pulse/pressu...
Pressure testing the world’s rapid regulatory response capabilities
When a novel virus emerges that has epidemic or pandemic potential, decisions have to be made fast: which vaccine candidates to move into trials, how trials should be designed, how to share data, and ...
www.linkedin.com
November 28, 2025 at 11:04 AM
CEPI’s November newsletter is out! 🗞️
This edition spotlights recent regulatory “pressure test” simulations in Brasilia and Mombasa, early clinical progress on a Lassa fever vaccine, new partnerships to speed up vaccine manufacturing and release, and lots more.
www.linkedin.com/pulse/pressu...
This edition spotlights recent regulatory “pressure test” simulations in Brasilia and Mombasa, early clinical progress on a Lassa fever vaccine, new partnerships to speed up vaccine manufacturing and release, and lots more.
www.linkedin.com/pulse/pressu...
CEPI’s new publication lays out the blueprint for equitable access at the heart of the organisation’s outbreak R&D.
Our Pathogen Archetype Frameworks details four pathogen archetypes, which ultimately guide CEPI’s access funding, advocacy, and catalysing efforts.
Learn more in the blog ⬇️
Our Pathogen Archetype Frameworks details four pathogen archetypes, which ultimately guide CEPI’s access funding, advocacy, and catalysing efforts.
Learn more in the blog ⬇️
A blueprint for access at the heart of outbreak R&D | CEPI
Discover how the type of pathogen guides CEPI's approach to access
cepi.net
November 26, 2025 at 2:29 PM
CEPI’s new publication lays out the blueprint for equitable access at the heart of the organisation’s outbreak R&D.
Our Pathogen Archetype Frameworks details four pathogen archetypes, which ultimately guide CEPI’s access funding, advocacy, and catalysing efforts.
Learn more in the blog ⬇️
Our Pathogen Archetype Frameworks details four pathogen archetypes, which ultimately guide CEPI’s access funding, advocacy, and catalysing efforts.
Learn more in the blog ⬇️
Join WAHO, CEPI & partners for a webinar launching the Lassa Fever Research Agenda & open-access Repository—key tools to guide research, inform policy, and support timely, equitable vaccine introduction.
📅 25 Nov | 🕛 12:00 GMT
🔗 Register: bit.ly/4i8pYxT
📅 25 Nov | 🕛 12:00 GMT
🔗 Register: bit.ly/4i8pYxT
November 20, 2025 at 2:52 PM
Join WAHO, CEPI & partners for a webinar launching the Lassa Fever Research Agenda & open-access Repository—key tools to guide research, inform policy, and support timely, equitable vaccine introduction.
📅 25 Nov | 🕛 12:00 GMT
🔗 Register: bit.ly/4i8pYxT
📅 25 Nov | 🕛 12:00 GMT
🔗 Register: bit.ly/4i8pYxT
A new CEPI-funded initiative with LumaCyte
and IDT Biologika aims to overcome a major hurdle in vaccine manufacturing: the slow, complex process of potency testing.
and IDT Biologika aims to overcome a major hurdle in vaccine manufacturing: the slow, complex process of potency testing.
November 19, 2025 at 2:58 PM
A new CEPI-funded initiative with LumaCyte
and IDT Biologika aims to overcome a major hurdle in vaccine manufacturing: the slow, complex process of potency testing.
and IDT Biologika aims to overcome a major hurdle in vaccine manufacturing: the slow, complex process of potency testing.
The Regionalized Vaccine Manufacturing Collaborative (RVMC) has released its first Status Report - a major step toward building sustainable, regionally-led vaccine manufacturing across Africa, Southeast Asia, and Latin America and the Caribbean.
Progress towards regionalised vaccine manufacturing remains uneven
The Regionalised Vaccine Manufacturing Collaborative (RVMC) has published its inaugural Regionalised Vaccine Manufacturing (RVM) Status Report. Thus, marking a pivotal step in understanding progress ...
rvmc.net
November 18, 2025 at 2:32 PM
The Regionalized Vaccine Manufacturing Collaborative (RVMC) has released its first Status Report - a major step toward building sustainable, regionally-led vaccine manufacturing across Africa, Southeast Asia, and Latin America and the Caribbean.
Sterility testing — ensuring vaccine batches are free from microbial contamination — can take up to a month.
With new CEPI funding of up to $199,238, USA-based CBio will develop a rapid sterility testing system based on its cellPhoresis™ technology.
With new CEPI funding of up to $199,238, USA-based CBio will develop a rapid sterility testing system based on its cellPhoresis™ technology.
November 13, 2025 at 3:24 PM
Sterility testing — ensuring vaccine batches are free from microbial contamination — can take up to a month.
With new CEPI funding of up to $199,238, USA-based CBio will develop a rapid sterility testing system based on its cellPhoresis™ technology.
With new CEPI funding of up to $199,238, USA-based CBio will develop a rapid sterility testing system based on its cellPhoresis™ technology.
The West African Health Organization(WAHO), with support from CEPI and other partners, have launched the first-ever Lassa Fever Vaccine Policy Research Agenda.
Read in full: bit.ly/4nTNVdO
Read in full: bit.ly/4nTNVdO
November 13, 2025 at 3:00 PM
The West African Health Organization(WAHO), with support from CEPI and other partners, have launched the first-ever Lassa Fever Vaccine Policy Research Agenda.
Read in full: bit.ly/4nTNVdO
Read in full: bit.ly/4nTNVdO
The world remains dangerously underprepared for future pandemics. A new report from the G20 HLIP – co-chaired by CEPI Board Chair, Jane Halton – warns urgent action is needed to close financing gaps and strengthen defences against biological threats.
Read the full report ⬇️
Read the full report ⬇️
Pandemic Financing
The G20 High Level Independent Panel sets minimum annual benchmarks for pandemic financing and urges governments to take action by or before the September
nam.edu
November 12, 2025 at 4:00 PM
The world remains dangerously underprepared for future pandemics. A new report from the G20 HLIP – co-chaired by CEPI Board Chair, Jane Halton – warns urgent action is needed to close financing gaps and strengthen defences against biological threats.
Read the full report ⬇️
Read the full report ⬇️
CEPI is truly honoured to receive Research!America’s 2026 Advocacy Award for Outstanding Achievement in Public Health.
The award recognises a public–private partnership that has made a critical and timely contribution to public health progress ⬇️
The award recognises a public–private partnership that has made a critical and timely contribution to public health progress ⬇️
Research!America Announces 2026 Advocacy Awards to Honor Nation’s Top Medical and Health Leaders - Research!America
Research!America urges the president and congressional leaders to come back to the table immediately to end the shutdown.
www.researchamerica.org
November 11, 2025 at 3:57 PM
CEPI is truly honoured to receive Research!America’s 2026 Advocacy Award for Outstanding Achievement in Public Health.
The award recognises a public–private partnership that has made a critical and timely contribution to public health progress ⬇️
The award recognises a public–private partnership that has made a critical and timely contribution to public health progress ⬇️
What do you know about CEPI's 100 Days Mission?
More than eight million people who died during the COVID-19 pandemic might be alive today if the world had achieved the 100 Days Mission to develop safe and effective new vaccines against the novel SARS-SoV-2 virus.
More than eight million people who died during the COVID-19 pandemic might be alive today if the world had achieved the 100 Days Mission to develop safe and effective new vaccines against the novel SARS-SoV-2 virus.
What would it take to achieve the 100 Days Mission?
What will it take for the world to develop, and enable access to safe and effective vaccines against new pathogens in 100 days? And why is it crucial that the world…
vimeo.com
November 7, 2025 at 3:09 PM
What do you know about CEPI's 100 Days Mission?
More than eight million people who died during the COVID-19 pandemic might be alive today if the world had achieved the 100 Days Mission to develop safe and effective new vaccines against the novel SARS-SoV-2 virus.
More than eight million people who died during the COVID-19 pandemic might be alive today if the world had achieved the 100 Days Mission to develop safe and effective new vaccines against the novel SARS-SoV-2 virus.
💡West Africa is one step closer to being protected against the deadly Lassa fever disease with IAVI's vaccine candidate, supported by CEPI, showing promise in the first stage of clinical testing.
Results from the Phase I trial are published in @nejm.org.
Results from the Phase I trial are published in @nejm.org.
IAVI’s Lassa fever vaccine shows promise in early clinical trials | CEPI
CEPI-backed research testing the vaccine candidate's safety and immunogenicity was published in the New England Journal of Medicine.
cepi.net
November 6, 2025 at 4:18 PM
💡West Africa is one step closer to being protected against the deadly Lassa fever disease with IAVI's vaccine candidate, supported by CEPI, showing promise in the first stage of clinical testing.
Results from the Phase I trial are published in @nejm.org.
Results from the Phase I trial are published in @nejm.org.
Broadly protective coronavirus vaccines could offer an alternative to the ‘one bug, one drug' approach.
We spoke to Dr Michael Osterholm, Director of CIDRAP, about a new CEPI-funded initiative mapping out research into all-in-one coronavirus vaccines ⬇️
cepi.net/big-one-comi...
We spoke to Dr Michael Osterholm, Director of CIDRAP, about a new CEPI-funded initiative mapping out research into all-in-one coronavirus vaccines ⬇️
cepi.net/big-one-comi...
The ‘Big One’ is coming: How can we prepare for a future coronavirus pandemic? | CEPI
Broadly protective coronavirus vaccines, built to protect us from multiple different future coronaviruses in one vaccine, could offer a vital
cepi.net
November 4, 2025 at 1:26 PM
Broadly protective coronavirus vaccines could offer an alternative to the ‘one bug, one drug' approach.
We spoke to Dr Michael Osterholm, Director of CIDRAP, about a new CEPI-funded initiative mapping out research into all-in-one coronavirus vaccines ⬇️
cepi.net/big-one-comi...
We spoke to Dr Michael Osterholm, Director of CIDRAP, about a new CEPI-funded initiative mapping out research into all-in-one coronavirus vaccines ⬇️
cepi.net/big-one-comi...